Sun Mei Zhen, Deckers Charles L P, Liu Yu Xi, Wang Wei
Department of Neurology, The First Hospital of Shanxi Medical University, Taiyuan, China.
Seizure. 2009 Mar;18(2):90-3. doi: 10.1016/j.seizure.2008.06.009. Epub 2008 Jul 30.
Evaluation of the efficacy of add-on valproate (VPA) or primidone (PRM) in patients with partial epilepsy unresponsive to carbamazepine (CBZ).
The trial was prospective and open. Patients, aged 8-58 years, with partial epilepsy who did not become seizure free on CBZ were randomized to either VPA add-on or PRM add-on. The baseline period and the evaluation period were both 3 months. Proportions of patients with different degrees of reduction in seizure frequency were determined.
Significantly more patients on VPA (51% of 68 patients) achieved a greater than 50% seizure reduction than on PRM (34% of 68 patients). There was no significant difference in percentage seizure free (26% and 16%, respectively) or in percentage treatment withdrawals due to adverse effects.
Our results indicated that the efficacy of the CBZ/VPA combination tends to be greater than the efficacy of the CBZ/PRM combination.
评估在对卡马西平（CBZ）无反应的部分性癫痫患者中加用丙戊酸盐（VPA）或扑米酮（PRM）的疗效。
该试验为前瞻性开放性试验。年龄在8至58岁之间、患有部分性癫痫且使用CBZ后仍未实现无癫痫发作的患者被随机分为加用VPA组或加用PRM组。基线期和评估期均为3个月。确定癫痫发作频率不同程度降低的患者比例。
使用VPA的患者（68例患者中的51%）癫痫发作减少超过50%的比例显著高于使用PRM的患者（68例患者中的34%）。无癫痫发作的百分比（分别为26%和16%）或因不良反应而停药的百分比无显著差异。
我们的结果表明，CBZ/VPA联合用药的疗效往往大于CBZ/PRM联合用药的疗效。
